Effects of antiarrhythmic agents on left ventricular function during exercise in patients with chronic left ventricular dysfunction

Annals of Nuclear Medicine
Yasuo TakadaToyoaki Murohara

Abstract

This study was designed to determine the effects of antiarrhythmic agents on global left ventricular (LV) function during exercise in patients with chronic LV dysfunction. Thirty-five patients with LV dysfunction [LV ejection fraction (LVEF) < 45%] and ventricular arrhythmias were studied. They were randomly classified into 3 groups: patients who received a single oral dose of 6 mg/kg disopyramide phosphate (n = 12), those who received a single oral dose of 4 mg/kg mexiletine hydrochloride (n = 12), and those who received a single oral dose of 4 mg/kg pilsicainide hydrochloride (n = 11). First, all patients were subjected to baseline rest and peak exercise, equilibrium-gated cardiac-pool scintigraphy with 99mTc-human serous albumin of 740 MBq (baseline data). Second, on a separate day, they were given drugs once, and were subsequently subjected to rest and peak exercise equilibrium-gated cardiac-pool scintigraphy. Exercise LVEF and peak ejection rate (PER) after administration were significantly lower in the disopyramide and pilsicainide groups than in the mexiletine group (p < 0.05, respectively). The changes in LVEF and PER from rest to peak exercise after administration were significantly less than the baseline changes in th...Continue Reading

References

Jun 1, 1977·British Journal of Clinical Pharmacology·I D BradbrookH J Rogers
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Nov 1, 1989·American Heart Journal·S S Gottlieb
Mar 1, 1988·The American Journal of Cardiology·UNKNOWN Cardiac Arrhythmia Pilot Study (CAPS) Investigators
Jan 1, 1987·Journal of the American College of Cardiology·A A de PaolaH R Kay
Nov 1, 1974·Journal of Clinical Pharmacology·J M Samet, B Surawicz
Aug 1, 1974·Clinical Pharmacology and Therapeutics·L A VismaraE A Amsterdam
Apr 1, 1984·Journal of Clinical Pharmacology·E M Vaughan Williams
May 15, 1983·The American Journal of Cardiology·J S GottdienerR D Fletcher
Aug 27, 1982·Deutsche medizinische Wochenschrift·H A Wester, N Mouselimis
Mar 13, 1980·The New England Journal of Medicine·P J PodridB Lown
Jun 1, 1960·The American Journal of Cardiology·E T ANGELAKOS, E P HASTINGS

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.